A tracking code will be sent out once your payment has been fully received
In a substudy of 178 patients from the SUSTAIN 8 trial on semaglutide as a diabetes treatment, the average proportion of lean mass loss was nearly identical at 40%, despite lower doses and less total weight loss than in the STEP 1 trial
doi: 10.2337/dci18-0033 39 McGillJBSubramanianS
In 2023, Black adults received only about 12 percent of prescriptions for popular anti-obesity drugs, while 85 percent went to White patients.21 This stark disparity underscores systemic inequities in the healthcare system, from provider bias to financial barriers, that disproportionately affect communities of color
Cureus Sinha R, Papamargaritis D, Sargeant JA, Davies MJ (2023) Efficacy and safety of tirzepatide in type 2 diabetes and obesity management
These treatments are perfect for restoring facial definition lost during weight loss